Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Nathan Kline Institute for Psychiatric Research
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00287820CT.gov Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism | — | Completed | — | — | — |
NCT00515723CT.gov Glucose and Lipid Metabolism on Antipsychotic Medication | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hyperglycemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Risperidone (this asset) | Nathan Kline Institute for Psychiatric Research | Approved | BB · 68 |
| Metformin | The First Affiliated Hospital of Xiamen University | P4 | BBB |
| Exenatide | Saint Luke's Health System | P4 | BB |
| Saffron | Birjand University of Medical Sciences | P4 | BB |
| Sitagliptin | Dawn Smiley MD | P4 | BB |
| Olanzapine | Washington University School of Medicine | P4 | BB |
| Capecitabine | Brigham and Women's Hospital | P4 | BB |
| Losartan | Brigham and Women's Hospital | P4 | BB |
| Liraglutide | The First Affiliated Hospital of Xiamen University | P4 | BB |
+26 more in the Hyperglycemia cohort
Other indications for Risperidone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Major Depressive Disorder | — | P4 | BBB · 78 |
| Psychotic Disorder | — | P4 | BBB · 77 |
| Schizoaffective Disorder | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Risperidone in Hyperglycemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/risperidone-hyperglycemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →